<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01760473</url>
  </required_header>
  <id_info>
    <org_study_id>#5879</org_study_id>
    <nct_id>NCT01760473</nct_id>
  </id_info>
  <brief_title>Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone</brief_title>
  <official_title>Reinforcing Effects of Intranasal Buprenorphine Versus Buprenorphine/Naloxone in Buprenorphine-maintained Intranasal Drug Users</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Indivior Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to compare the abuse liabilities of intranasal buprenorphine and
      buprenorphine/naloxone in individuals who are physically dependent on sublingual
      buprenorphine. The investigators hypothesize that the abuse liability of
      buprenorphine/naloxone is lower than that of buprenorphine alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although sublingual buprenorphine is an effective treatment for opioid addiction, the
      medication itself has abuse liability and, in some countries, has largely replaced heroin as
      the opioid drug of choice. In response to the reports of diversion and abuse of sublingual
      (SL) buprenorphine, a potentially less abusable formulation of buprenorphine that contains
      naloxone is being marketed in several countries. However, the relative abuse liability of
      buprenorphine alone and the buprenorphine/naloxone combination in buprenorphine-dependent
      individuals is unclear. Preliminary data from a study funded by Schering-Plough Corporation
      suggest that the buprenorphine/naloxone combination, when given intravenously (IV), does
      indeed have less abuse liability than IV buprenorphine in buprenorphine-dependent
      individuals. In addition to IV abuse of buprenorphine, epidemiological data suggest that
      buprenorphine is widely abused by the intranasal (IN) route. However, no data exist on the
      abuse liability of either IN buprenorphine alone or the buprenorphine/naloxone combination.
      Several studies have shown that naloxone is an effective antagonist of opioid agonist effects
      when given intravenously, but it is not clear whether naloxone given intranasally is as
      effective as when it is given by other routes of administration. Some studies have suggested
      that they are equally effective (Loimer et al., 1994), but others have shown that naloxone
      given intranasally is less effective (i.e., has a slower onset of effects) than when given by
      other routes of administration (Kelly et al., 2005). How this may impact on the ability of
      naloxone to reduce the reinforcing effects of IN buprenorphine is unclear. The primary aim of
      the current study proposal is to compare the reinforcing effects of IN buprenorphine and
      buprenorphine/naloxone in IN opioid abusers who are maintained on SL buprenorphine using a
      study design parallel to that used in our recent studies of the abuse liability of IV
      buprenorphine and buprenorphine/naloxone. Placebo, heroin, and naloxone will be used as
      neutral, positive, and negative controls, respectively. Secondary aims are to compare the
      subjective, performance, and physiological effects of IN buprenorphine and
      buprenorphine/naloxone. Overall, this study will complement our investigations of IV
      buprenorphine products by allowing for a complete overview within the same laboratory
      self-administration model of both the intravenous and intranasal abuse liability of
      buprenorphine versus buprenorphine/naloxone in individuals maintained on buprenorphine. The
      primary aim of the study is to compare the reinforcing effects of IN buprenorphine and IN
      buprenorphine/naloxone in opioid abusers maintained on different doses of sublingual
      buprenorphine. Secondary aims of the study are to compare the subjective, performance and
      physiological effects of IN buprenorphine and IN buprenorphine/naloxone. IN-administered
      placebo (lactose powder), naloxone alone, and heroin alone will be tested as neutral,
      negative, and positive control conditions, respectively. Participants (N=12 completers) will
      reside on an inpatient unit (5-South) during a 7 to 8-week study. This research will provide
      useful information to clinicians treating opioid dependent individuals with buprenorphine,
      and importantly, will provide information about the abuse potential and effects of
      buprenorphine on multiple measures of human functioning.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>In this study's design, all participants received each of the 9 intranasal test drugs under investigation. This study employed a Latin-square randomization procedure, therefore, the sequence of testing for the 9 intranasal drugs was unique for each participant.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drug Self-administration</measure>
    <time_frame>Throughout the testing sessions (approximately 9 weeks).</time_frame>
    <description>The maximum number of responses (clicks on a computer mouse) the participant was willing to perform in order to receive a dose of the intranasal challenge drug under investigation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SOWS</measure>
    <time_frame>Throughout the testing sessions (approximately 9 weeks).</time_frame>
    <description>Subjective opioid withdrawal scale (SOWS) measure (0-64). Greater score indicates more severe withdrawal.</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Heroin Dependence</condition>
  <arm_group>
    <arm_group_label>Bup 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intranasal challenge drug: 8 mg of Buprenorphine administered intranasally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bup 16</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intranasal challenge drug: 16 mg of Buprenorphine administered intranasally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bup/Nal 8/2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intranasal challenge drug: 8 mg of Buprenorphine administered intranasally with 2 mg of Naloxone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bup/Nal 8/8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intranasal challenge drug: 8 mg of Buprenorphine administered intranasally with 8 mg of Naloxone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bup/Nal 8/16</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intranasal challenge drug: 8 mg of Buprenorphine administered intranasally with 16 mg of Naloxone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bup/Nal 16/4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intranasal challenge drug: 16 mg of Buprenorphine administered intranasally with 4 mg of Naloxone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heroin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intranasal challenge drug: 24 mg of heroin administered intranasally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Intranasal challenge drug: Intranasal lactose powder.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naloxone 4 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intranasal challenge drug: Intranasal Naloxone 4mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal challenge drug</intervention_name>
    <description>Each of the experimental challenge drugs were administered intranasally to all participants in random order.</description>
    <arm_group_label>Bup 8</arm_group_label>
    <arm_group_label>Bup 16</arm_group_label>
    <arm_group_label>Bup/Nal 8/2</arm_group_label>
    <arm_group_label>Bup/Nal 8/8</arm_group_label>
    <arm_group_label>Bup/Nal 8/16</arm_group_label>
    <arm_group_label>Bup/Nal 16/4</arm_group_label>
    <arm_group_label>Heroin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Naloxone 4 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DSM IV criteria for heroin dependence

          -  No major mood, psychotic, or anxiety disorder

          -  Physically healthy

          -  Able to perform study procedures

          -  21-45 years of age

          -  Normal body weight

          -  Current use of opioids in amounts and/or frequencies that meet or exceed those used in
             the proposed study (e.g., 1-2 bags of heroin per occasion at least twice per day)

          -  Self-administer IN buprenorphine above placebo levels during the qualification phase
             (see below)

        Exclusion Criteria:

          -  DSM IV criteria for dependence on drugs other than opioids, nicotine or caffeine

          -  Participants requesting treatment

          -  Participants on parole or probation

          -  Pregnancy or lactation

          -  Birth, miscarriage or abortion within 6 months

          -  Current or recent history of significant violent behavior

          -  Current major Axis I psychopathology, other than opioid dependence (e.g., mood
             disorder with functional impairment or suicide risk, schizophrenia), that might
             interfere with ability to participate in the study

          -  AST or ALT &gt; 3 times the upper limit of normal

          -  Significant suicide risk

          -  Current chronic pain

          -  Sensitivity, allergy, or contraindication to opioids

          -  Current or recent (past 30 days) physical dependence on or treatment with methadone,
             buprenorphine, or the buprenorphine/naloxone combination
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra Comer, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute and Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2009</study_first_submitted>
  <study_first_submitted_qc>January 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2013</study_first_posted>
  <results_first_submitted>October 11, 2016</results_first_submitted>
  <results_first_submitted_qc>August 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 8, 2017</results_first_posted>
  <last_update_submitted>August 7, 2017</last_update_submitted>
  <last_update_submitted_qc>August 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>opioid dependence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heroin Dependence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Buprenorphine, Naloxone Drug Combination</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intranasal Challege Drug</title>
          <description>Each of the 9 experimental challenge drugs were administered intranasally to all participants in random order. This study employed a Latin-square randomization procedure, therefore, the testing order of the 9 IN doses was unique for each participant.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intranasal Challege Drug</title>
          <description>Each of the 9 experimental challenge drugs were administered intranasally to all participants in random order.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.3" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Drug Self-administration</title>
        <description>The maximum number of responses (clicks on a computer mouse) the participant was willing to perform in order to receive a dose of the intranasal challenge drug under investigation.</description>
        <time_frame>Throughout the testing sessions (approximately 9 weeks).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bup 8</title>
            <description>Intranasal challenge drug: 8 mg of Buprenorphine administered intranasally.
Intranasal challenge drug: Each of the experimental challenge drugs were administered intranasally to all participants in random order.</description>
          </group>
          <group group_id="O2">
            <title>Bup 16</title>
            <description>Intranasal challenge drug: 16 mg of Buprenorphine administered intranasally.
Intranasal challenge drug: Each of the experimental challenge drugs were administered intranasally to all participants in random order.</description>
          </group>
          <group group_id="O3">
            <title>Bup/Nal 8/2</title>
            <description>Intranasal challenge drug: 8 mg of Buprenorphine administered intranasally with 2 mg of Naloxone.
Intranasal challenge drug: Each of the experimental challenge drugs were administered intranasally to all participants in random order.</description>
          </group>
          <group group_id="O4">
            <title>Bup/Nal 8/8</title>
            <description>Intranasal challenge drug: 8 mg of Buprenorphine administered intranasally with 8 mg of Naloxone.
Intranasal challenge drug: Each of the experimental challenge drugs were administered intranasally to all participants in random order.</description>
          </group>
          <group group_id="O5">
            <title>Bup/Nal 8/16</title>
            <description>Intranasal challenge drug: 8 mg of Buprenorphine administered intranasally with 16 mg of Naloxone.
Intranasal challenge drug: Each of the experimental challenge drugs were administered intranasally to all participants in random order.</description>
          </group>
          <group group_id="O6">
            <title>Bup/Nal 16/4</title>
            <description>Intranasal challenge drug: 16 mg of Buprenorphine administered intranasally with 4 mg of Naloxone.
Intranasal challenge drug: Each of the experimental challenge drugs were administered intranasally to all participants in random order.</description>
          </group>
          <group group_id="O7">
            <title>Heroin</title>
            <description>Intranasal challenge drug: 24 mg of heroin administered intranasally.
Intranasal challenge drug: Each of the experimental challenge drugs were administered intranasally to all participants in random order.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Intranasal challenge drug: Intranasal lactose powder.
Intranasal challenge drug: Each of the experimental challenge drugs were administered intranasally to all participants in random order.</description>
          </group>
          <group group_id="O9">
            <title>Naloxone 4 mg</title>
            <description>Intranasal challenge drug: Intranasal Naloxone 4mg.
Intranasal challenge drug: Each of the experimental challenge drugs were administered intranasally to all participants in random order.</description>
          </group>
        </group_list>
        <measure>
          <title>Drug Self-administration</title>
          <description>The maximum number of responses (clicks on a computer mouse) the participant was willing to perform in order to receive a dose of the intranasal challenge drug under investigation.</description>
          <units>Clicks on a computer mouse</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="12"/>
                <count group_id="O9" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="350" spread="135"/>
                    <measurement group_id="O2" value="255" spread="121"/>
                    <measurement group_id="O3" value="223" spread="113"/>
                    <measurement group_id="O4" value="113" spread="83"/>
                    <measurement group_id="O5" value="2.7" spread="2.7"/>
                    <measurement group_id="O6" value="191" spread="112"/>
                    <measurement group_id="O7" value="755" spread="156"/>
                    <measurement group_id="O8" value="38" spread="23"/>
                    <measurement group_id="O9" value="45" spread="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SOWS</title>
        <description>Subjective opioid withdrawal scale (SOWS) measure (0-64). Greater score indicates more severe withdrawal.</description>
        <time_frame>Throughout the testing sessions (approximately 9 weeks).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bup 8</title>
            <description>Intranasal challenge drug: 8 mg of Buprenorphine administered intranasally.
Intranasal challenge drug: Each of the experimental challenge drugs were administered intranasally to all participants in random order.</description>
          </group>
          <group group_id="O2">
            <title>Bup 16</title>
            <description>Intranasal challenge drug: 16 mg of Buprenorphine administered intranasally.
Intranasal challenge drug: Each of the experimental challenge drugs were administered intranasally to all participants in random order.</description>
          </group>
          <group group_id="O3">
            <title>Bup/Nal 8/2</title>
            <description>Intranasal challenge drug: 8 mg of Buprenorphine administered intranasally with 2 mg of Naloxone.
Intranasal challenge drug: Each of the experimental challenge drugs were administered intranasally to all participants in random order.</description>
          </group>
          <group group_id="O4">
            <title>Bup/Nal 8/8</title>
            <description>Intranasal challenge drug: 8 mg of Buprenorphine administered intranasally with 8 mg of Naloxone.
Intranasal challenge drug: Each of the experimental challenge drugs were administered intranasally to all participants in random order.</description>
          </group>
          <group group_id="O5">
            <title>Bup/Nal 8/16</title>
            <description>Intranasal challenge drug: 8 mg of Buprenorphine administered intranasally with 16 mg of Naloxone.
Intranasal challenge drug: Each of the experimental challenge drugs were administered intranasally to all participants in random order.</description>
          </group>
          <group group_id="O6">
            <title>Bup/Nal 16/4</title>
            <description>Intranasal challenge drug: 16 mg of Buprenorphine administered intranasally with 4 mg of Naloxone.
Intranasal challenge drug: Each of the experimental challenge drugs were administered intranasally to all participants in random order.</description>
          </group>
          <group group_id="O7">
            <title>Heroin</title>
            <description>Intranasal challenge drug: 24 mg of heroin administered intranasally.
Intranasal challenge drug: Each of the experimental challenge drugs were administered intranasally to all participants in random order.</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Intranasal challenge drug: Intranasal lactose powder.
Intranasal challenge drug: Each of the experimental challenge drugs were administered intranasally to all participants in random order.</description>
          </group>
          <group group_id="O9">
            <title>Naloxone 4 mg</title>
            <description>Intranasal challenge drug: Intranasal Naloxone 4mg.
Intranasal challenge drug: Each of the experimental challenge drugs were administered intranasally to all participants in random order.</description>
          </group>
        </group_list>
        <measure>
          <title>SOWS</title>
          <description>Subjective opioid withdrawal scale (SOWS) measure (0-64). Greater score indicates more severe withdrawal.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="12"/>
                <count group_id="O9" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread=".5"/>
                    <measurement group_id="O2" value="3" spread=".7"/>
                    <measurement group_id="O3" value="3" spread=".9"/>
                    <measurement group_id="O4" value="3" spread=".8"/>
                    <measurement group_id="O5" value="5" spread="1"/>
                    <measurement group_id="O6" value="3" spread=".5"/>
                    <measurement group_id="O7" value="2" spread=".3"/>
                    <measurement group_id="O8" value="2" spread=".53"/>
                    <measurement group_id="O9" value="7" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the day of admission until discharge and at 3 month follow-up</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intranasal Challege Drug</title>
          <description>Each of the 9 experimental challenge drugs were administered intranasally to all participants in a randomized order. Therefore, the testing sequence for each of the participants was unique. Although we assessed for some averse events on a daily basis, other measures of health (e.g., blood chemistry) were assessed on a weekly basis. As multiple doses were tested during the week, therefore, in some cases we cannot causally connect some AEs to any individual drug/testing condition.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated liver function test (AST/ALT)</sub_title>
                <description>Liver function rose to greater than 3 x the upper limit of normal. Blood chemistry was performed on a weekly basis throughout the 9 weeks. As multiple doses were tested during the week, we cannot attribute this AE to any individual drug condition.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Sandra Comer</name_or_title>
      <organization>New York State Psychiatric Institute</organization>
      <phone>646 774-6146</phone>
      <email>sdc10@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

